37 DAFTAR PUSTAKA
1. Mac TL, Tran DS, Quet F, Odermatt P, Preux PM, Tan CT. Epidemiology, aetiology and clinical management of epilepsy in Asia: Lancet Neurol. 2007; 6: 5333-43
2. Arzimanoglou AA, Guerrini R, Aicardi J. General principles of managment. Dalam: Arzimanoglou AA, Guerrini R, Aicardi J, penyunting. Aichardis epilepsy in children. Edisi ke-3. Philadelphia: Lippincott williams and wilkins; 2004. h.354-62
3. Valsanis HA, Arora SK, Labbab B, McFarlane SI. Antiepileptic drugs and bone metabolism, nutrition dan metabolism. 2006; 3:36
4. Carney PW, Prowse MA, Scheffer IE. Epilepsy syndromes in children. Australia Family Physician. 2005; 34: 1009-15
5. Naik N. Guidelines for diagnosis and management of childhood epilepsy. Indian pediatrics.2009: 46:681 -98
6. Hwang H, Kim KJ. New antiepileptic drugs in pediatric epilepsi. Brain Dev. 2008 ;30:549 -55
7. Verrotti A, Coppola G, parisi P, Mohn A. Chiarelli. F. Bone and calcium metabolism and antiepileptic drugs. Clinical Neurology and Neurosurgery. 2010; 1-10
8. Pack AM, Gidal B, Vazquez B. Bone disease associated with antiepileptic drugs. Cleve clin J Med. 2004. 71 Suppl 2;542-8
9. Babayigit A, Dirik E, Bober E, Cakmachi H. Adverse effects of antiepileptic drugs on bone mineral clensity. Pediatr Neurol. 2006; 35: 177-81
10. Sheth RD. Bone Health in Epilepsy. International League Against Epilepsy 2002; 43(12):1453-4
11. M. Alism. Pack, the association between antiepileptic drugs and bone disease. Epilepsy currents. 2003:91-5
12. Ecevit C, Aydogan A, Kavachi T, Altinoz S. Effect of karbamazepine and valproate on bone mineral density. Pediatric Neural 2004; 31:279-82
13. Buluk A, Guzelipek M, Savh H, Temel I, Ozisik HI, Kaygusuz A. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacological Research. 2004; 50:93-97
14. Ganong WF: Pengendalian hormonal pada metabolisme kalsium dan fisiologi tulang. Dalam: Ganong WF, penyunting. Fisiologi Kedokteran Edisi ke-17. Appleton and Lange, 1995.h.367-80
15. Holm IA. Disorders of bone metabolism. Dalam: Brook CG, Clayton PE, Brown RS, Savage MO, penyunting. Clinical Pediatric Endocrinology. Edisi ke-5. UK: Blackwell; 2005. h.280-519
16. Cashman KD. Diet, nutrition, and bone health. J Nutr 2007;137:2507s-12s 17. Kelenjar paratiroid, gangguan metabolisme tulang dan kalsium. Dalam:
38 18. Flynn A. The role of dietary calcium in bone health. Proceedings Nutri
Society 2003; 62:851-8
19. Camfield PR, Camfield CS. Pediatric epilepsy: an overview. Dalam: Swaimann KF, Ashwal S, Ferriero VM, penyunting. Pediatric Neurology Principles & Practice. Edisi ke-1. Philadelphia: Mosby Inc; 2006.h.980-9. 20. Arzimanoglou A, Guerrini R, Aicardi J. Epilepsy: overview and definitions.
Dalam: Arzimanoglou A, Guerrini R, Aicardi J, penyunting. Aicardi’s Epilepsy in Children. Edisi ke-3. USA: Maple press; 2004.h.1-7.
21. Panayiotopoulos CP. Principles of therapy in epilepsies. Dalam: Panayiotopoulos CP, penyunting. The Epilepsies Seizures, Syndromes and Management. Edisi ke-1. UK: Bladon medical publishing; 2005.h.59-80. 22. Conway JM, Kriel RL, Birnbaum AK. Antiepileptic drug therapy in children.
Dalam: Swaimann KF, Ashwal S, Ferriero VM, penyunting. Pediatric Neurology Principles & Practice. Edisi ke-1. Philadelphia: Mosby Inc; 2006.h.1105-26
23. Arzimanoglou A, Guerrini R, Aicardi J. Medical treatment . Dalam: Arzimanoglou A, Guerrini R, Aicardi J, penyunting. Aicardi’s Epilepsy in Children. Edisi ke-3. USA: Maple press; 2004.h.363-86
24. Monti B, Polazzi E, Contestabile A. Biochemical, molecular, and epigenetic mechanism of valproic acid neuroprotection. Curr Mol Pharmacol. 2009;2:95-109.
25. Thilothammal N, Banu K, Ratnam RS. Comparison of phenobarbitone, phenytoin with sodium valproate:randomized, double-blind study. Indian J Pediatr. 1996;33:549-55.
26. Noureen N, Rana MT. Does steady state serum level of valproic acid correlate with dose, seiure response, and frequency of adverse drug reactions in Pakistani children with epilepsy?. Pediatric Neurol. 2011;9:333-9.
27. Bourgeois BF.Valproate. Dalam: Pellock JM, Bourgeois RFD, Dodson WE,
Nordli DR, penyunting. Pediatric Epilepsy. Edisi ke-3 New
York:Demos;2008.h.685-98
28. Abaci A, Saygi M, Yis U, Demir K, Dirik E, Bober E. Metabolic alterations during valproic acid treatment : a prospective study. Pediatric meurol. 2009; 41:435-9
29. A.Edgar, Samaniego, D. Raj, Sheth. Bone consequences of epilepsy and antiepleptic medications. Semin Pediatr neutol. 2007; 14:196-200
30. Greer FR, Krebs NF. Comitee on Nutrition. Optimizing bone health and calcium intakes of infants, children, and adolescents. Pediatrics 2006; 117:578-85
31. Lanou AJ, Berkow SE, Barnard ND. Calcium, Dairy Products, and Bone Health in Children and Young Adults: A Reevaluation of the Evidence. Pediatrics 2005;115:736-43
39 33. Bueno AL, Czepielewski MA. The importance for growth of dietary intake of
calcium and vitamin D. J Pediatr. 2008; 84:386-94
34. Derman O, Cinemre A, Kanbur N, Dogan M, Kilic M, Karaduman E. Effect of swimming on bone metabilsm in adolescents. Pediatrics. 2008; 50:149-54 35. Tekgul H, Serdaroglu G, Huseyinov A, Gokben S. Bone mineral status in
pediatric outpatients on antiepileptic drug monotherapy. Pediatrics. 2006; 21:411-414
36. Oner N, Karasalihoglu S, Karaca H, Celtik C, Tutunouler F. Bone mineral metabolism changes in epileptic children receiving valproic acid. Pediatric 2004;40:470-473
